Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$24.06 +0.1%	$24.15	$20.92 ▼ $42.48	$45.54B	N/A	195,604 shs	148,323 shs
MKKGY Merck KGaA	$25.83 -0.3%	$26.27	$24.32 ▼ $39.17	$16.74B	0.92	113,736 shs	167,606 shs
TAK Takeda Pharmaceutical	$14.42 -2.2%	$14.83	$12.80 ▼ $15.53	$46.90B	0.23	2.03 million shs	3.64 million shs
UCBJY UCB	$101.30 +0.4%	$93.90	$71.16 ▼ $106.60	N/A	0.51	33,024 shs	16,018 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	+3.00%	+9.77%	+0.80%	+10.07%	-37.49%
MKKGY Merck KGaA	+0.19%	-3.07%	+1.03%	-2.67%	-23.30%
TAK Takeda Pharmaceutical	+0.15%	-0.59%	-1.03%	+0.35%	+7.57%
UCBJY UCB	+1.63%	-0.03%	+11.55%	+29.54%	+30.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MKKGY Merck KGaA	3.1224 of 5 stars	0.0	3.0	2.5	0.0	2.4	0.0	3.1
TAK Takeda Pharmaceutical	2.0054 of 5 stars	0.0	5.0	2.5	0.0	2.8	0.0	0.6
UCBJY UCB	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
MKKGY Merck KGaA	3.00	Buy	N/A	N/A
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
UCBJY UCB	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest MKKGY, TAK, DSNKY, and UCBJY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/16/2025	UCBJY UCB	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$12.39B	3.68	$1.26 per share	19.15	$5.61 per share	4.29
MKKGY Merck KGaA	$22.57B	0.74	$8.12 per share	3.18	$50.22 per share	0.51
TAK Takeda Pharmaceutical	$30.09B	1.53	$3.11 per share	4.64	$14.39 per share	1.00
UCBJY UCB	$6.66B	N/A	$3.97 per share	25.53	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.95B	$1.03	23.36	22.07	1.23	15.65%	17.92%	8.61%	7/29/2025 (Estimated)
MKKGY Merck KGaA	$3.00B	$2.11	12.23	12.60	1.97	13.23%	9.61%	5.59%	8/7/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	65.55	8.74	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)
UCBJY UCB	$1.15B	N/A	0.00	23.56	0.67	N/A	N/A	N/A	7/23/2025 (Estimated)

Latest MKKGY, TAK, DSNKY, and UCBJY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	N/A	MKKGY Merck KGaA	$0.48	N/A	N/A	N/A	$5.34 billion	N/A
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
5/15/2025	Q1 2025	MKKGY Merck KGaA	$0.50	$0.59	+$0.09	$0.59	$5.32 billion	$5.89 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
4/25/2025	Q4 2025	DSNKY Daiichi Sankyo	N/A	$0.30	N/A	$0.30	N/A	$3.40 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	$0.29	1.21%	N/A	28.16%	N/A
MKKGY Merck KGaA	$0.34	1.32%	N/A	16.11%	N/A
TAK Takeda Pharmaceutical	$0.55	3.81%	N/A	250.00%	N/A
UCBJY UCB	$0.48	0.47%	N/A	N/A	N/A

Latest MKKGY, TAK, DSNKY, and UCBJY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/21/2025	UCBJY UCB		$0.4838	0.62%	4/28/2025	4/29/2025	5/14/2025
4/23/2025	MKKGY Merck KGaA		$0.3382	1.25%	4/29/2025	4/30/2025	5/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.53	1.85
MKKGY Merck KGaA	0.23	1.31	0.83
TAK Takeda Pharmaceutical	0.57	1.01	0.52
UCBJY UCB	0.30	1.36	0.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	0.10%
TAK Takeda Pharmaceutical	9.17%
UCBJY UCB	N/A

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	N/A
TAK Takeda Pharmaceutical	0.04%
UCBJY UCB	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
MKKGY Merck KGaA	62,557	646.21 million	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
UCBJY UCB	9,378	N/A	N/A	Not Optionable

MKKGY, TAK, DSNKY, and UCBJY Headlines

Recent News About These Companies

UCB (OTCMKTS:UCBJY) Upgraded at The Goldman Sachs Group

July 18 at 2:13 AM | americanbankingnews.com

UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 16 at 6:22 AM | msn.com

UCB SA’s Growth Potential: Buy Rating on Bimzelx’s Transformative Impact

July 16 at 2:48 AM | tipranks.com

Here's What Could Help UCB (UCBJY) Maintain Its Recent Price ... - Nasdaq

July 11, 2025 | nasdaq.com

Here's What Could Help UCB (UCBJY) Maintain Its Recent Price Strength

July 9, 2025 | msn.com

TD Cowen maintains UCB stock Buy rating, EUR250 target

March 27, 2025 | uk.investing.com

UCB SA (UCBJY)

February 2, 2025 | finance.yahoo.com

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

January 17, 2025 | finance.yahoo.com

UCB (OTC:UCBJY) Stock Quotes, Forecast and News Summary

November 22, 2024 | benzinga.com

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

November 20, 2024 | benzinga.com

Biogen, UCB release phase 3 data on lupus candidate dapirolizumab

November 19, 2024 | msn.com

Oruka draws buy at Stifel on potential against psoriasis

October 11, 2024 | msn.com

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

September 26, 2024 | finance.yahoo.com

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

September 24, 2024 | finance.yahoo.com

UCB gets expanded FDA approval for psoriasis drug Bimzelx

September 23, 2024 | seekingalpha.com

UCB United Community Banks, Inc.

August 29, 2024 | seekingalpha.com

Barclays Sticks to Its Buy Rating for UCB SA (0NZT)

August 27, 2024 | markets.businessinsider.com

Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies

August 26, 2024 | msn.com

DAY BY DAY Upgrades UCB SA - Depositary Receipt () (UCBJY)

August 12, 2024 | msn.com

Barclays Remains a Buy on UCB SA (0NZT)

July 29, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks
The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
By Leo Miller | July 2, 2025
View The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why

MKKGY, TAK, DSNKY, and UCBJY Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$24.06 +0.02 (+0.08%)

As of 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Merck KGaA OTCMKTS:MKKGY

$25.83 -0.08 (-0.31%)

As of 03:59 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Takeda Pharmaceutical NYSE:TAK

$14.42 -0.32 (-2.17%)

Closing price 03:59 PM Eastern

Extended Trading

$14.42 +0.01 (+0.03%)

As of 04:53 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

UCB OTCMKTS:UCBJY

$101.30 +0.39 (+0.39%)

As of 03:58 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time